MD-76R SUMMARY
MD-76®R
[ DIATRIZOATE MEGLUMINE AND
DIATRIZOATE SODIUM INJECTION U.S.P.]
MD-76R (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Intended for intravascular administration, MD-76R contains 66% w/v 1-deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6, triiodobenzoate (salt) and 10% w/v monosodium 3,5-diacetamido-2,4,6, triiodobenzoate.
MD-76R is indicated in excretion urography, aortography, pediatric angiocardiography, peripheral arteriography, selective renal arteriography, selective visceral arteriography, selective coronary arteriography with or without left ventriculography, contrast enhancement of computed tomographic brain imaging and for intravenous digital subtraction angiography.
MD-76R is also indicated for the contrast enhancement in body computed tomography. (See Clinical Pharmacology). Continuous or multiple scans separated by intervals of 1-3 seconds during the first 30-90 seconds post-injection of the contrast medium (dynamic CT scanning) provide enhancement of diagnostic significance. Subsets of patients in whom delayed body CT scans might be helpful have not been identified. Inconsistent results have been reported and abnormal and normal tissues may be isodense during the time frame used for delayed CT scanning. The risks of such indiscriminate use of contrast media are well known and such use is not recommended. At present, consistent results have been documented using dynamic CT techniques only.
|
NEWS HIGHLIGHTSMedia Articles Related to MD-76R (Diatrizoic Acid / Diatrizoic Acid)
Experts Propose 'Global Health Accellerator' To Help New Drugs, Diagnostics, Vaccines Reach Distant Markets
Source: Immune System / Vaccines News From Medical News Today [2009.11.04]
Research firms in developing countries have a medicine cabinet full of affordable and innovative drugs, diagnostics and vaccines on shelves or in development to address "neglected tropical diseases" but need help to get such products to more potential users.
FDA Publishes Guidance On Diagnostic Tests For 2009 H1N1 Influenza Virus
Source: Flu / Cold / SARS News From Medical News Today [2009.11.03]
The U.S. Food and Drug Administration published a guidance document that should help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus. Although there are not any FDA-approved or cleared tests that diagnose this specific infection, during this pandemic, manufacturers can submit a request to the FDA for an Emergency Use Authorization (EUA).
Rapid Growth Scoops Pathology Diagnostics Erbi Award
Source: Medical Devices / Diagnostics News From Medical News Today [2009.10.30]
The rapid organic growth and commercial potential of newcomer Pathology Diagnostics Ltd. has won it the 2009 ERBI Start-up Award, which is sponsored by the East of England Development Agency. Pathology Diagnostics Ltd. has achieved a six figure turnover without upfront equity investment. It provides a one-stop solution for human tissue diagnostics.
Ascent Healthcare Solutions Receives 510(K) Clearance To Reprocess Biosense Webster SoundStar™ 3D Diagnostic Ultrasound Catheter
Source: Medical Devices / Diagnostics News From Medical News Today [2009.10.29]
Ascent Healthcare Solutions, a leader in delivering healthcare resource sustainability, announced that it has received the industry's first and only 510(k) clearance from the U.S. Food and Drug Administration (FDA) to reprocess the Biosense Webster SoundStar™ 3D Diagnostic Ultrasound Catheter. With this new clearance, Ascent continues to lead the charge in bringing sustainability to healthcare.
Greater Use Of In-Patient Diagnostic Imaging Improves Patient Outcomes Without Significantly Impacting Costs
Source: MRI / PET / Ultrasound News From Medical News Today [2009.10.29]
Hospitals that make greater use of inpatient diagnostic imaging exams achieve lower in-hospital mortality rates with little or no impact on costs, according to a peer-reviewed study of more than 1 million patient outcomes in more than 100 hospitals nationwide published in the November issue of the Journal of the American College of Radiology (JACR).
Published Studies Related to MD-76R (Diatrizoic Acid / Diatrizoic Acid)
Powdered diatrizoic acid for radiography of the respiratory tract. Part II. Clinical application. [1991.11]
The diagnostic and clinical value of 41 examinations using insufflation and/or inhalation of powdered diatrizoic acid for tracheobronchography, tracheography, laryngography, nasopharyngography, and sinusography was investigated in 35 patients. Diatrizoic acid was found to be useful when applied by insufflation for demonstration of the nasopharynx, trachea and greater bronchi, especially in patients with airway stenosis and low pulmonary reserve...
Powdered diatrizoic acid for radiography of the respiratory tract. Part I. Experimental investigation. [1991.09]
Powdered diatrizoic acid as a contrast medium administered by inhalation and insufflation for visualization of the airways was tested in vitro and in 21 dogs. Good radiopacity of the contrast medium and its antibacterial activity was found in vitro... Histologic and ultrastructural examinations after contrast studies showed phagocytic reaction to diatrizoic acid, transient impairment of production of surfactant, reactive changes of bronchial mucosa, and no fibrotic changes in the long-term observation.
|
|
|
|
Page last updated: 2009-11-04
|
